Day: May 17, 2025

Data confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”) In new echocardiographic analysis, TX45 treatment resulted in sustained hemodynamic effects for 29 days TX45 improved cardiac and pulmonary hemodynamics in PH-HFpEF patients across a range of left ventricular ejection fractions (“LVEF”), including LVEF≥50% and LVEF 41-49%WATERTOWN, Mass., May 17, 2025 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) today announced the complete results from Part A of the Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), which are being presented in a late-breaking,...

Data suggests that single dose of RJVA-001 leads to durable metabolic improvements with low systemic GLP-1 exposure in db/db mouse model of T2D— potentially simultaneously addressing durability, adherence, and tolerability challenges seen with current GLP-1 drugs Endoscopic ultrasound-guided delivery achieves targeted pancreatic expression in a large animal model with no toxicity observed to date Data show nutrient-responsive GLP-1 secretion in human beta cells and human islets, demonstrating that Rejuva mimics natural hormone regulation rather than constant drug-driven stimulation Rejuva advancing toward first-in-human studies; first CTA module submission for RJVA-001 expected by June 2025 BURLINGTON, Mass., May 17, 2025 (GLOBE NEWSWIRE) — Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused...

 rcadis 2025 Annual General MeetingArcadis’ shareholders re-appoint Supervisory Board members and approve dividendShareholders re-appointed Michiel Lap and Carla Mahieu to the Supervisory Board Shareholders approved the company’s dividend proposal of €1.00 per ordinary shareAmsterdam, 17 May 2025 – Arcadis (EURONEXT: ARCAD), the world’s leading company in delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets, confirms that all resolutions that were brought up for vote were adopted during its annual General Meeting earlier today. Michiel Lap was reappointed to the Supervisory of Arcadis N.V. for a final term of two years. Mr. Lap has been a member of the Supervisory Board since 2015, and Chair of the Supervisory Board since 2022. Mr. Lap will remain Chair of the Supervisory...

VANCOUVER, British Columbia, May 16, 2025 (GLOBE NEWSWIRE) — SHARC International Systems Inc. (CSE: SHRC) (FSE: IWIA) (OTCQB: INTWF) (“SHARC Energy” or the “Company”) is pleased to announce that the Company has entered into a short-term working capital loan agreement for up to $400,000 (the “Loan”). The Loan matures on July 31, 2025, subject to mutual agreement for extension, and bears interest at an annual rate of 8%. The Loan is secured against all present and after acquired assets of the Company. The Loan will be used for working capital purposes as SHARC Energy works through the working capital cycle of several SHARC and PIRANHA projects that are to be delivered over the next three months. In consideration of the Loan, the Company issued 800,000 stock options (the “Options”). Each Option entitles the holder thereof...